Correcting Overall Survival for the Impact of Crossover Via a Rank-Preserving Structural Failure Time (RPSFT) Model in the RECORD-1 Trial of Everolimus in Metastatic Renal-Cell Carcinoma

Author： Korhonen P.  

Publisher： Taylor & Francis Ltd

ISSN： 1054-3406

Source： Journal of Biopharmaceutical Statistics, Vol.22, Iss.6, 2012-11, pp. : 1258-1271

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Reflex sympathetic dystrophy in patients with metastatic renal cell carcinoma treated with Everolimus

By Massard Christophe   Fizazi Karim   Gross-Goupil Marine   Escudier Bernard  

Investigational New Drugs, Vol. 28, Iss. 6, 2010-12 ,pp. : 879-881

Springer Publishing Company

Access to resources Recommend Favorite

Everolimus: In Advanced Renal Cell Carcinoma

By Garnock-Jones Karly P.   Keating Gillian M.  

Drugs, Vol. 69, Iss. 15, 2009-10 ,pp. : 2115-2124

Adis International

Access to resources Recommend Favorite

Pneumonitis associated with everolimus in the RECORD-1 trial

By  

Reactions Weekly, Vol. 1, Iss. 1295-1296, 2010-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite

An indirect comparison of everolimus versus sorafenib in metastatic renal cell carcinoma – a flawed analysis?

By Hoaglin David C   Cislo Paul R  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 7, 2012-05 ,pp. : 1077-1078

Informa Healthcare

Access to resources Recommend Favorite

An indirect comparison of everolimus versus sorafenib in metastatic renal cell carcinoma - a flawed analysis and a problematic response

By Hoaglin David C  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 12, 2013-08 ,pp. : 1705-1706

Informa Healthcare

Access to resources Recommend Favorite